The Trump administration is expected to liberalise research into psychedelic-assisted therapies – and Emyria investors have ...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Fraser Palamara ...

The company's FDA-approved drug Sofdra is the first for the common and embarrassing condition of excessive sweating.

The US election failed to deliver extra Chinese stimulus measures companies had been banking on, affecting copper and iron ...

Bank stocks, including CBA, see losses this morning Gold falls below US$2,600, hurting gold stocks; lithium drops on weak ...

MA Moelis rates Carnaby a Buy with a high target, while RBC gives FireFly an Outperform rating on its Green Bay project.

EBR Systems is among ASX healthcare stocks with upcoming catalysts, expecting feedback on a FDA substantive review expected ...

Stockhead’s ‘Garimpeiro’ columnist Barry FitzGerald is back in the studio for another instalment of The Explorers Podcast.

Category four exploration works have been approved allowing C29 (ASX:C29) to carry out a range of tenement-wide activities at ...

Bitcoin’s bounce to record highs in recent days is only the beginning of a fresh surge higher for crypto, says US billionaire ...

The ASX dipped again as mining and energy stocks fell, with Paladin Energy slashing its guidance and seeing shares drop more than 20pc.

Koba Resources’ step-out drilling has intersected significant uranium at the Chivas and Berber prospects at its Yarramba ...